Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
Find out how Optimi Health’s UK psilocybin export could reshape psychedelic trial supply and what risks remain for Phase 2 research.
Pharma & Biotech
Features & Analysis
How the PharmAla Biotech Holdings Inc. and Jupiter Neurosciences, Inc. deal reflects changing investor expectations in psychedelics
Explore why the PharmAla and Jupiter Neurosciences licensing deal could reshape investor sentiment around next-generation psychedelic therapeutics.
Pharma & Biotech
Psyence Biomedical Ltd. advances natural psilocybin development with Phase IIb cancer distress trial
Psyence Biomedical Ltd. advances natural psilocybin therapy in a Phase IIb cancer distress trial. Explore what this means for psychedelic medicine development.